Table 3.
VAHL incidences in the study groups
| All-PET group(n = 137) | All patients with hematologic malignancy | Lymphoma patients | Myeloma patients | |
| (n = 137) | (n = 102) | (n = 34) | ||
| no VAHL | 94 (68.6%) | 71 (69.6%) | 22 (64.7%) | |
| VAHL | 43 (31.4%) | 31 (30.4%) | 12 (35.3%) | |
| grade 1–2 VAHL | 31 (22.6%) | 21 (20.6%) | 10 (29.4%) | |
| grade 3–4 VAHL | 12 (8.8%) | 10 (9.8%) | 2 (5.9%) | |
|
PET-1 group (n = 51) |
All patients with hematologic malignancy | Lymphoma patients | Myeloma patients | |
| (n = 51) | (n = 39) | (n = 11) | ||
| no VAHL | 38 (74.5%) | 29 (74.4%) | 8 (72.7%) | |
| VAHL | 13 (25.5%) | 10 (25.6%) | 3 (27.3%) | |
| grade1–2 VAHL | 11 (21.6%) | 9 (23.1%) | 2 (18.2%) | |
| grade 3–4 VAHL | 2 (3.9%) | 1 (2.6%) | 1 (9.1%) | |
|
PET-2 group (n = 86) |
All patients with hematologic malignancy | Lymphoma patients | Myeloma patients | |
| (n = 86) | (n = 63) | (n = 23) | ||
| no VAHL | 56 (65.1%) | 42 (66.7%) | 14 (60.9%) | |
| VAHL | 30 (34.9%) | 21 (33.3%) | 9 (39.1%) | |
| grade 1–2 VAHL | 20 (23.3%) | 12 (19.0%) | 8 (34.8%) | |
| grade 3–4 VAHL | 10 (11.6%) | 9 (14.3%) | 1 (4.3%) |
Categorical variables are reported as frequency and percentage. All-PET group refers to all patients with hematologic malignancy that underwent [18F]FDG PET-CT after BNT162b2 administration. PET-1 group includes those received the first vaccine dose only before imaging, and PET-2 group includes those received the booster dose as well